<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004225</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067466</org_study_id>
    <secondary_id>ECOG-8597</secondary_id>
    <nct_id>NCT00004225</nct_id>
  </id_info>
  <brief_title>Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Pilot Trial of Adenovirus p53 and Radiotherapy on Nonsmall Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's&#xD;
      ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of gene therapy plus radiation therapy in&#xD;
      treating patients who have non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility and tolerability of adenovirus p53 gene therapy and&#xD;
           radiotherapy in patients with non-small cell lung cancer with or without prior&#xD;
           radiotherapy to the indicator lesion(s).&#xD;
&#xD;
        -  Determine p53 and p21 expression and induction of apoptosis and necrosis in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Assess any vector incorporation, antitumor response, local control, viral dissemination,&#xD;
           and development of adenovirus antibodies in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified by prior radiotherapy to the&#xD;
      indicator lesion(s) (yes vs no).&#xD;
&#xD;
      Adenovirus p53 is injected directly into an endobronchial lesion via bronchoscopy or into&#xD;
      locoregional tumors via multiple percutaneous punctures under fluoroscopic, ultrasonic, or CT&#xD;
      scan guidance on days 1, 3, and 8. Patients undergo radiotherapy beginning on day 2 and&#xD;
      continuing for a total of 10 days.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5CMV-p53 gene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven non-small cell lung cancer with at least 1 lesion accessible for&#xD;
             endobronchial or percutaneous injection&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Must have a requirement for palliative radiotherapy to the thorax&#xD;
&#xD;
          -  Clinically stable enough to undergo 3 adenovirus injections&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active systemic viral, bacterial, or fungal infection requiring treatment&#xD;
&#xD;
          -  No concurrent illness requiring hospitalization or IV medications or psychologic,&#xD;
             familial, sociologic, geographic, or other concurrent condition that would preclude&#xD;
             adequate follow up and compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior adenoviral gene therapy&#xD;
&#xD;
          -  Any number of any type of other prior biologic therapy allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Any number of any type of prior chemotherapy allowed&#xD;
&#xD;
          -  At least 2 weeks since prior systemic cancer therapy and no worse than grade 2&#xD;
             toxicity in any organ&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Any number of any type of prior endocrine therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy greater than 50 Gy if prior and concurrent radiation fields&#xD;
             include the spinal cord&#xD;
&#xD;
          -  No prior radiotherapy in fraction sizes greater than 2 Gy with the spinal cord in the&#xD;
             concurrent radiation field&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since surgical resection of lung tissue&#xD;
&#xD;
          -  At least 2 weeks since any other prior surgery requiring general anesthesia and&#xD;
             recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan H. Schiller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 3, 2010</last_update_submitted>
  <last_update_submitted_qc>July 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

